Cobalis Corp., of Irvine, Calif., appointed S. Wayne Kay, Ellen McDonald and Thomas Silberg to its board.
Cougar Biotechnology Inc., of Los Angeles, appointed Richard Phillips vice president of regulatory affairs and quality assurance.
Epiphany Biosciences Inc., of San Francisco, said Roger Kornberg is joining its scientific advisory board.
Epitome Biosystems, of Waltham, Mass., appointed Jeffrey Radding vice president, research and development.
EPIX Pharmaceuticals Inc., of Lexington, Mass., appointed Charles Dinarello and Edward Roberts to its scientific advisory board
ESBATech AG, of Zurich, Switzerland, appointed Martin Gertsch chief financial officer.
FBR Capital Markets Corp., of Arlington, Va., the principal subsidiary of Friedman, Billings, Ramsey Group Inc., said Thomas Crowley Jr., David Moskowitz, Jeffrey Swarz and Ryan Stewart joined the firm's health care investment banking group.
FibroGen Inc., of South San Francisco, appointed Sarah O'Dowd vice president and general counsel.
Gen-Probe Inc., of San Diego, said Carl Hull joined the company as executive vice president and chief operating officer.
Gloucester Pharmaceuticals Inc., of Cambridge, Mass., appointed Donald Hayden vice chairman.
InNexus Biotechnology Inc., of Vancouver, British Columbia, appointed Heinz Kohler chief scientific officer.
Innovative Biosensors Inc., of College Park, Md., hired Joanne Stephenson as head of strategic marketing and Richard Thomas as vice president of business development.
Innovive Pharmaceuticals Inc., of New York, appointed Angelo De Caro to serve on its board and audit committee.
Inotek Pharmaceuticals Corp., of Beverly, Mass., added Davey Scoon and Dennis Langer to its board.
Inspire Pharmaceuticals Inc., of Durham, N.C., promoted Benjamin Yerxa to chief scientific officer and executive vice president, strategic operations; Joseph Schachle to executive vice president and chief of commercial operations; and Gerald St. Peter to senior vice president, sales and field operations.
Labopharm Inc., of Laval, Quebec, appointed Mary Anne Heino to the new position of vice president sales and marketing. Also, it appointed Julia Brown to its board.
LifeCycle Pharma A/S, of Horsholm, Denmark, appointed Peter Nielsen senior vice president of pharmaceutical development and chief medical officer.
Lipid Sciences Inc., of Pleasanton, Calif., said Philip Barter and John Kastelein joined its scientific advisory board.
Maxygen Inc., of Redwood, Calif., appointed Santosh Vetticaden chief medical officer.
MedImmune Inc., of Gaithersburg, Md., appointed Jamie Harrell vice president, infectious disease marketing, and Mark Stanton vice president, managed markets.
Microbix Biosystems Inc., of Toronto, appointed Vaughn Embro-Pantalony to its board.
Nabi Biopharmaceuticals, of Boca Raton, Fla., appointed Leslie Hudson, a director, interim CEO and president, and Geoffrey Cox, a director, as non-executive chairman. That followed the resignation of Thomas McLain from those positions.
Neurobiological Technologies Inc., of Emeryville, Calif., appointed Warren Wasiewski vice president of clinical programs, and appointed William Fletcher to its board.
Neurogen Corp., of Branford, Conn., appointed Arunee Changchit vice president, drug metabolism and pharmacokinetics; Jeffrey Dill vice president, general counsel and secretary; and Ricardo Ochoa vice president, preclinical safety.
OncoMed Pharmaceuticals, of Redwood City, Calif., appointed Steven Benner senior vice president and chief medical officer.
Oramed Pharmaceuticals Inc., of Jerusalem, added Ele Ferrannini to its scientific advisory board.
Oxford Genome Sciences, of Oxford, UK, has appointed Mike Gresser to its scientific advisory board.
Panacos Pharmaceuticals Inc., of Watertown, Mass., said Tom Lategan joined the company as vice president of regulatory affairs.
PDL BioPharma Inc., of Fremont, Calif., said Mark McCamish joined the company as senior vice president and chief medical officer. It also promoted Richard Murray to executive vice president and chief scientific officer, and appointed him to the board.
Pharmos Corp., of Iselin, N.J., has appointed Elkan Gamzuto chief executive officer. He will succeed Haim Aviv who will continue as chairman of the board.
Pipex Pharmaceuticals Inc., of Ann Arbor, Mich., appointed Daniel Dorman and James Kuo to its board.
Pozen Inc., of Durham, N.C., appointed Jacques Rejeange to its board.